News

ASX
LCT 0.023   Last updated EOD 23rd April 2018
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheet provides a summary of our current business and research pipeline.

News

— 11 April 2018

LCT Strategy Update

Since the AGM, LCT’s Board and management have been working diligently, focused on developing a robust, well-considered and comprehensive strategy; one that makes the best use of our expertise, proprietary assets, partnerships and available funds to give shareholders the best chance of achieving a return on your investment. This is an outline of that strategy.

Read More Read Less

— 22 February 2018

Half yearly report ended 31 December 2017

In the half yearly report for the six months ended 31 December 2017 the consolidated operating loss after income tax for the period 1 July to 31 December 2017 was $1.8m (2016 loss $2.1 m). The main reason for the decreased loss is that during the period, no patients in the Phase IIb clinical trial of NTCELL® for Parkinson’s disease were treated and no NTCELL was produced.

Read More Read Less

— 25 January 2018

LCT to sell JV shares for $3m and receive DIABECELL® licence

Living Cell Technologies Limited (LCT) has agreed to sell its 50% shareholding in joint venture company, Diatranz Otsuka Limited (DOL), to the other 50% shareholder, Otsuka Pharmaceutical Factory, Inc. (OPF), for $3m, with settlement on 31 January 2018. In association with this, LCT and DOL have agreed to sign a memorandum of understanding, upon completion of sale of the shareholding, to exclusively license LCT to use DIABECELL in Australia, Argentina and New Zealand when it is FDA approved, and to supply product on favourable terms.

Read More Read Less
Load More

— 21 December 2017

NTCELL® and Parkinson’s clinical trial update

At its December meeting, Living Cell Technologies’ Board determined that NTCELL remains the primary focus of its research and development efforts. The 3 year follow-up of its Phase I/IIa clinical trial of NTCELL in Parkinson’s disease gives preliminary evidence of persistent long term improvement in some recipients.

Read More Read Less

— 15 November 2017

Results of voting at the AGM

Results of voting at the 2017 AGM

Read More Read Less

— 15 November 2017

Presentation to AGM - Dr Ken Taylor, CEO

Presentation to Annual General Meeting by Dr Ken Taylor, CEO

Read More Read Less
Load More

— 22 December 2016

Group 2 Parkinson’s Trial Patients’ Treatment Completed

Living Cell Technologies Limited has completed treatment of all six patients in group 2 of the Phase IIb clinical trial of NTCELL® for Parkinson’s disease, at Auckland City Hospital. Four patients had 80 NTCELL microcapsules implanted into the putamen on each side of their brain, and two patients had sham surgery with no NTCELL implanted.

Read More Read Less

— 21 December 2016

Appendix 3B

The Appendix 3B announced on 6 December 2016 stated 74,117,647 shares were to be issued. Due to rounding 74,117,653 have been issued. An amended Appendix 3B is attached.

Read More Read Less

— 14 December 2016

Notice of Ceasing to be a Substantial Holder

Form 605 - Corporations Act 2001, Section 671B

Notice of ceasing to be a substantial holder

Otsuka Pharmaceutical Factory, Inc ceased to be a substantial holder in Living Cell Technologies on 6 December 2016.

Read More Read Less
Load More

— 20 September 2015

2016 Annual General Meeting and Director Nominations

LCT's Annual General Meeting will be held at The Sheraton on the Park, 161 Elizabeth Street, Sydney on Wednesday 16 November 2016.

Read More Read Less

— 18 December 2015

LCT complies with ASIC infringement notice

Living Cell Technologies Limited has complied with an infringement notice from Australian Securities & Investments Commission related to an alleged contravention of its disclosure obligations under ASX listing rules in connection with the NTCELL® Clinical Study in Parkinson’s Meets Endpoints announcement made on 15 June 2015.

Read More Read Less

— 2 December 2015

LCT secures supply of NTCELL

Living Cell Technologies Limited has completed contracts to secure the supply and manufacture of NTCELL. The purchase of plant, designated pathogen-free pigs and inventory is estimated to increase cash outflows by approximately $50,000 for each of the next 12 months. The facilities will provide sufficient capacity to manufacture NTCELL for the Phase IIb clinical trial of NTCELL for Parkinson’s disease and to treat and charge patients under provisional consent.

Read More Read Less
Load More

— 15 December 2014

LCT completes patient implants in Parkinson's trial

The final patient has been successfully implanted in LCT's Phase I/IIa clinical trial of regenerative cell therapy NTCELL® for Parkinson’s disease. The operation took place at Auckland City Hospital last week.

Read More Read Less

— 8 December 2014

Share purchase plan cleansing statement

Share Purchase Plan - Cleansing Notice

Read More Read Less

— 8 December 2014

Appendix 3B: New issue announcement

New issue announcement, application for quotation of additional securities and agreement.

Read More Read Less
Load More

— 19 December 2013

Withdrawal of NTCELL pre-clinical study

Living Cell Technologies Limited today announced that it is withdrawing the publication of the pre-clinical study of the effects of NTCELL in a rat model of Parkinson’s disease. The data will also be withdrawn from all regulatory documentation.

Read More Read Less

— 19 November 2013

Results of the AGM held on 19 November 2013

The following voting results in respect of the resolutions laid before Members at the Annual General Meeting of Living Cell Technologies Ltd held today are provided in accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act.

Read More Read Less

— 19 November 2013

Managing Director's Presentation to the AGM

View Dr Andrea Grant's presentation to the Annual General Meeting held on 19 November 2013.

Read More Read Less
Load More

— 17 December 2012

Open Briefing: CEO on NTCELL Deal

— 10 December 2012

LCT Appoints Chief Science and Medical Officer

— 22 November 2012

LCT Starts Phase IIb Trial in Argentina

Load More

— 28 December 2011

LCT appoints Chief Executive

— 28 November 2011

AGM Chairman's Address

— 28 November 2011

AGM CEO's Address

Load More

— 31 December 2010

LCT Executes AUD 5,750,000 Funding Agreement

— 23 December 2010

LCT Negotiating Funding

— 20 December 2010

LCT Approved to Further Expand DIABECELL® NZ Trial

Load More

— 21 December 2009

LCT signs research and collaboration agreement to license encapsulation technology

— 11 December 2009

LCT extends SPP closing date until 17 December 2009

— 16 November 2009

LCT announces share purchase plan

Load More
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.